Navigation Links
Watson Launches Generic Exelon®
Date:7/1/2010

MORRISTOWN, N.J., July 1 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) announced today that, under a settlement with Novartis Pharmaceuticals Corporation, Novartis Pharma AG, Novartis AG, Novartis International Pharmaceutical Ltd., and Proterra AG (collectively "Novartis"), Watson has commenced shipment of a generic version of Exelon® (rivastigmine tartrate) 1.5mg, 3mg, 4.5mg and 6mg capsules.  Exelon® is used to treat dementia (a brain disorder that affects the ability to remember, think clearly, communicate, and perform daily activities and may cause changes in mood and personality) in people with Alzheimer's disease.

Under the terms of the settlement agreement announced on December 6, 2007, Novartis granted Watson a license to its U.S. patents covering Exelon® for a generic version of Exelon®. Further details concerning the settlement have not been disclosed. Watson's Abbreviated New Drug Application for its generic version of Exelon® was approved by the U.S. Food and Drug Administration on January 8, 2008.

For the twelve months ending April 30, 2010, Exelon® had total U.S. sales of approximately $425 million according to IMS Health data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release.  It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31,2009 and Watson's quarterly report on Form 10-Q for the period ended March 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Exelon® is a registered trademark of Novartis AG Corporation.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100121/LA41294LOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone-related Assets
2. Watson to Present at the Wells Fargo Securities 2010 Healthcare Conference
3. Watson Confirms Columbia Laboratories Filing of Definitive Proxy Relating to Watsons Acquisition of U.S. Rights to CRINONE® Progesterone Gel Product Line
4. Watsons Generic VALTREX® 500 mg and 1000 mg Receives FDA Approval
5. Watson Launches Generic Version of LIPITOR® in Canada
6. Watson to Present at the 2010 Citi Investment Research Global Healthcare Conference
7. Watson Reaches Settlement with Teva Over Seasonale(R)
8. Watson Confirms EVISTA(R) Patent Challenge
9. Watson Pharmaceuticals to Webcast Annual Meeting of Stockholders on May 7th
10. Watson To Present at Bank Of America/Merrill Lynch 2010 Healthcare Conference
11. Watson Confirms Trilipix(R) Patent Challenge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today announced financial results ... and updated its financial outlook for fiscal 2017. ... third quarter, Hill-Rom reported earnings of $0.09 per diluted ... prior-year period. These results reflect after-tax special items, including ... to the non-cash write-down of assets associated with the ...
(Date:7/27/2017)... 27, 2017  Zimmer Biomet Holdings, Inc. (NYSE and ... June 30, 2017.  The Company reported second quarter net ... the prior year period, and an increase of 2.1% ... points of contribution from the LDR Holding Corporation acquisition, ... quarter of 2016, or 0.3% on a constant currency ...
(Date:7/26/2017)... 2017 E.I. Medical Imaging (EIMI) has partnered ... custom design the worlds first ultrasound system to be used ... native habitat. In preparation for a piece produced by ... Week, Dr. Guttridge approached EIMI with the idea of an ... hammerhead sharks underwater. ...
Breaking Medicine Technology:
(Date:8/20/2017)... Centennial, CO (PRWEB) , ... August 20, 2017 , ... ... in the same household? If so, you may be interested in participating in ... The purpose of this research is to understand more about the relational aspects of ...
(Date:8/19/2017)... ... August 18, 2017 , ... Paragon ... transparent, verifiable database to help the cannabis industry move towards greater legitimacy. By ... deliver a faster technology with lower fees. Paragon will build a fully verifiable ...
(Date:8/19/2017)... Toronto, ON (PRWEB) , ... August 19, 2017 , ... ... of the of NaturallyCurly.com® The Curl Leaders, Editors’ Choice 2017 Award for the second ... must-have accessory for hair stylists and curlies alike was voted Best Moisturizer for Type ...
(Date:8/19/2017)... (PRWEB) , ... August 19, 2017 , ... ... NJ, is a diverse community of over 1,000 passionate employees, caregivers, volunteers, thought ... After Parker at Stonegate changed ownership, it was time to refresh the carpeting ...
(Date:8/18/2017)... , ... August 19, 2017 , ... ... Authority of Thailand presided over the Amazing Thailand Health and Wellness Tourism Showcase ... , Mr. Noppadon Pakprot, Deputy Governor for Tourism Products and Business at TAT ...
Breaking Medicine News(10 mins):